No Data
No Data
Maipu Medical (301033): The proportion of new products continues to increase, and the initial form of the second growth curve has emerged.
Performance Summary: The company released the 2024 annual report and the first quarter report for 2025. In 2024, the company achieved revenue of 0.278 billion yuan, a year-on-year increase of 20.61%; the net income attributable to the parent company's owners was 0.79.
MaiPu Medical (301033): A regenerative medicine platform company, striving for innovation to embrace growth.
Event: On April 25, 2025, the company announced its annual performance for 2024 and the first quarter of 2025. For the entire year of 2024, the company achieved revenue of 0.278 billion yuan (+20.61%), with net income attributable to the parent company.
Maipu Medical (301033): Centralized procurement helps to increase product volume, and profitability is gradually strengthening.
Event: The company released its 2024 annual report and the first quarter report for 2025, achieving revenue of 0.278 billion yuan in 2024 (yoy +20.61%), and net income of 0.079 billion yuan (yoy +92.9%), excluding
Maipu Medicine: 2024 Annual Report Summary
Maipu Medicine: 2024 Annual Report
Maipu Medical: Report for the first quarter of 2025